As part of the settlement, Stimwave has agreed to cease commercialization of all high frequency spinal cord stimulation systems, globally, in exchange for dismissal of the lawsuit with no damages assessed. The settlement pertains exclusively to spinal cord stimulation (SCS) and does not affect in any way Stimwave’s commercialization of its peripheral nerve stimulation (PNS) products for chronic pain management.
Joe Montana Professional Football Hall of Famer Joins Stimwave Technologies As Official Spokesperson
“After years of dealing with the residual effects of my professional football career, I am excited to have found this battery-free, minimally-invasive alternative to opioids that relieves chronic pain and I’m eager to help other chronic pain sufferers receive this life-changing micro-implant,” said Montana.
Freedom Neuro BV
Freedom Neuro BV, a medical device distributor for Stimwave Technologies Incorporated, today announced CE Mark approval for the world’s first Percutaneous Injectable Anchor System. The injectable anchor is utilized in conjunction with the company’s wireless neurostimulator devices...
Stimwave Announces Regulatory Approval from Australian Therapeutic Goods Administration (TGA) for its Freedom Spinal Cord Stimulation System
April 7, 2017 Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) for its Freedom Spinal Cord Stimulation (SCS) System. Stimwave will be...